Want to see IL:TEVA full AI Analyst Report?
TEVA Stock Chart & Stats
9580.00
-80.00(-0.84%)
At close: 4:00 PM EDT
9580.00
-80.00(-0.84%)
Day’s Range― - ―
52-Week Range5,305.00 - 11,350.00
Previous CloseN/A
Volume1.19M
Average Volume (3M)1.92M
Market Cap
₪126.60B
Enterprise Value154.00K
Total Cash (Recent Filing)₪3.63B
Total Debt (Recent Filing)₪16.76B
Price to Earnings (P/E)55.6
Beta0.52
Next Earnings
Nov 11, 2026EPS Estimate
216.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.64
Shares Outstanding1,164,638,700
10 Day Avg. Volume1,312,069
30 Day Avg. Volume1,917,294
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)4.58
Price to Sales (P/S)1.94
P/FCF Ratio14.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)6.07
Revenue Forecast (FY)₪49.90B
Bulls Say, Bears Say
Bulls Say
Strong Free Cash FlowSustained high free cash flow and strong FCF growth provide durable cash resources to fund R&D, deleveraging, targeted M&A, and reinvestment without relying on equity raises. This bolsters financial optionality and resilience over multiple quarters as transformation executes.
Innovation-Driven Revenue GrowthA rapid pivot to innovation—now a much larger share of revenue—diversifies Teva away from sole reliance on generics. Durable uptake of AUSTEDO/AJOVY/UZEDY and rising innovation mix supports higher-margin sales and structural revenue growth if clinical/payer dynamics remain favorable.
Improving Margins & TargetsMeasured margin expansion and firm multi-year targets signal sustainable operating leverage from mix shift and transformation programs. Consistent margin improvement supports profit durability, cash conversion goals and credibility with rating agencies as execution continues.
Bears Say
Elevated LeverageMaterial leverage limits financial flexibility and raises refinancing and interest-service risk if earnings soften. Although improving from prior years, sustained debt levels constrain agility for large investments or cyclical downturns and lengthen the timeline to reach target capital structure.
Sharp Revenue Contraction TTMA severe trailing‑twelve‑month revenue drop reduces scale benefits and puts pressure on absolute profitability and cash coverage ratios. Reversing such a decline requires sustained product launches and generics stability; until then revenue volatility remains a structural headwind.
Generics Concentration & High‑Value LossDependence on a few high-value generics creates concentration risk: losing one key SKU materially reduces revenue and EBITDA. Persistent pricing competition and fewer high‑value launches in key regions make generics revenue a structurally erratic cash source absent continued innovation gains.
Teva News
TEVA FAQ
What was Teva Pharmaceutical Industries Limited’s price range in the past 12 months?
Teva Pharmaceutical Industries Limited lowest stock price was 5305.00 and its highest was 11350.00 in the past 12 months.
What is Teva Pharmaceutical Industries Limited’s market cap?
Teva Pharmaceutical Industries Limited’s market cap is ₪126.60B.
When is Teva Pharmaceutical Industries Limited’s upcoming earnings report date?
Teva Pharmaceutical Industries Limited’s upcoming earnings report date is Nov 11, 2026 which is in 99 days.
How were Teva Pharmaceutical Industries Limited’s earnings last quarter?
Teva Pharmaceutical Industries Limited released its earnings results on Jul 29, 2026. The company reported 6.2 earnings per share for the quarter, missing the consensus estimate of 15.6 by -9.4.
Is Teva Pharmaceutical Industries Limited overvalued?
According to Wall Street analysts Teva Pharmaceutical Industries Limited’s price is currently Overvalued.
Does Teva Pharmaceutical Industries Limited pay dividends?
Teva Pharmaceutical Industries Limited pays a Quarterly dividend of 8.5 which represents an annual dividend yield of N/A. See more information on Teva Pharmaceutical Industries Limited dividends here
What is Teva Pharmaceutical Industries Limited’s EPS estimate?
Teva Pharmaceutical Industries Limited’s EPS estimate is 216.5.
How many shares outstanding does Teva Pharmaceutical Industries Limited have?
Teva Pharmaceutical Industries Limited has 1,164,638,700 shares outstanding.
What happened to Teva Pharmaceutical Industries Limited’s price movement after its last earnings report?
Teva Pharmaceutical Industries Limited reported an EPS of 6.2 in its last earnings report, missing expectations of 15.6. Following the earnings report the stock price went up 10.172%.
Which hedge fund is a major shareholder of Teva Pharmaceutical Industries Limited?
Currently, no hedge funds are holding shares in IL:TEVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited operates as a prominent global pharmaceutical firm, involved in the research, development, manufacturing, marketing, and distribution of generic, specialized, and biopharmaceutical products throughout North America, Europe, and other international regions. The company's diverse portfolio encompasses sterile preparations, hormonal therapies, high-potency drugs, and cytotoxic substances, supplied in a wide array of dosage forms such as tablets, capsules, injectable solutions, inhalants, oral liquids, transdermal patches, topical ointments, and creams. Furthermore, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). A significant portion of its research and product development is concentrated on the central nervous system, pain management, respiratory illnesses, and oncology. Leading products for the central nervous system include Copaxone, utilized for relapsing multiple sclerosis; AJOVY, an option for migraine prevention; and AUSTEDO, prescribed for tardive dyskinesia and chorea linked to Huntington's disease. Within the respiratory domain, addressing asthma and chronic obstructive pulmonary disease, Teva offers products like ProAir, QVAR, various Digihaler and RespiClick formulations, along with BRALTUS and CINQAIR/CINQAERO. Their oncology division features treatments such as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. The company also collaborates with MedinCell on the creation and commercialization of multiple extended-release injectable products, including a risperidone suspension designed for individuals with schizophrenia. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
TEVA Revenue Breakdown
54.45% North America
32.42% Europe
13.12% International Markets
